Who
Richard A. Miller
President and CEO
Company insider
Files Form 4 as: President and CEO, Corvus Pharmaceuticals; Director, Bolt Biotherapeutics; Pres, CEO & Director, Pharmacyclics.
In numbers
- Trades disclosed
- 77
- Buys
- 37
- Sells
- 0
- Bought
- $3.6M
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 23 May 2006
- Last trade
- 18 May 2026
- Last filed
- 20 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 May 2026filed 20 May 2026 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $60K5,000 at $12.05 | filing |
| 18 May 2026filed 20 May 2026 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $23K1,932 at $12.01 | filing |
| 18 May 2026filed 20 May 2026 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $60K5,000 at $12.05 | filing |
| 18 May 2026filed 20 May 2026 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $23K1,932 at $12.01 | filing |
| 4 Dec 2025filed 8 Dec 2025 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 7 May 2025filed 9 May 2025 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —559,073 | filing |
| 7 May 2025filed 9 May 2025 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $2.0M559,073 at $3.50 | filing |
| 20 Dec 2024filed 23 Dec 2024 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —750,000 at $0.00 | filing |
| 10 May 2024filed 14 May 2024 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —302,016 at $0.00 | filing |
| 6 May 2024filed 7 May 2024 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code P | —559,073 | filing |
| 6 May 2024filed 7 May 2024 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $999K577,634 at $1.73 | filing |
| 6 Dec 2023filed 8 Dec 2023 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 12 Jun 2023filed 14 Jun 2023 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 31 Mar 2023filed 3 Apr 2023 | CRVS Corvus Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 14 Dec 2022filed 16 Dec 2022 | BOLT Bolt Biotherapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 14 Dec 2022filed 15 Dec 2022 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $7,80010,000 at $0.78 | filing |
| 13 Dec 2022filed 15 Dec 2022 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $37K50,000 at $0.74 | filing |
| 28 Sep 2022filed 28 Sep 2022 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $19K25,000 at $0.76 | filing |
| 20 Sep 2022filed 20 Sep 2022 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $9,96312,300 at $0.81 | filing |
| 20 Sep 2022filed 20 Sep 2022 | CRVS Corvus PharmaceuticalsBiotechnology | SEC FORM 4 Bought | $2,2142,700 at $0.82 | filing |
News
No headline names them, or the companies they trade most, lately.